Yaqing Qie

A Standalone PD-1 Chimeric Switch Receptor T-Cell Platform Expands the Therapeutic Window of PD-L1 Targeting in Solid Tumors

This paper develops a PD-1 chimeric switch receptor T-cell platform that improves tumor targeting while reducing toxicity to normal cells in PD-L1-targeted therapies.

Single CAR-Dual target: Intracranial Delivery of Anti-PD-L1 CAR T Cells Effectively Eradicates Glioma and Immunosuppressive Cells in the Tumor Microenvironment.

This study develops a PD-L1-targeting CAR T cell therapy, MC9999, which effectively eradicates glioblastoma and immunosuppressive cells in the tumor microenvironment through intracranial delivery.